Patrick Lucy, VP of Business Development - Pfenex
Patrick Lucy, VP of Business Development - Pfenex.
Senior Vice President & CBO Protein Expression Business, Lig Pharmaceutical
Search every verified Patrick Lucy interview, podcast appearance, and on-the-record quote โ each transcript cross-checked by AI and human review to confirm speaker identity. In a 2013 interview at the BIO convention, Patrick Lucy, then Vice President of Business Development and Marketing at Pfenex, described the company as a venture-backed biotechnology firm based in San Diego, California. He stated that the company possessed a novel protein expression technology platform used to generate a pipeline of biosimilars and novel vaccines. Lucy noted that Pfenex had recently pivoted from being a technology and service provider to becoming a product development company, a transition he described as a "great upside" for the organization. He also mentioned that the company had announced a joint venture with Agile Biotech to develop a series of six biosimilars, with the first product expected to enter the clinic later that year. Lucy, who said he had been attending the BIO convention since 1993, advised other attendees to research the partnering system thoroughly before meetings to maximize value. He characterized the conference's attendees as "high value business folks" and praised the venue and location.
“Phoenix is a venture-backed biotechnology company based in San Diego, California. What we have is a novel protein expression technology platform that we've used to generate a broad pipeline of biosimilars as well as novel vaccines.”
“Being able to transition from a platform technology to a product company has been a great upside for the company.”
“Recently we've pivoted to becoming a product development company so the development of a pipeline of biosimilars as well as a couple novel vaccines has really positioned the company for growth and value growth.”
“Last week we announced a joint venture to develop a series of six biosimilars with Agile Biotech, and those products will be the first product we enter during the clinic later this year.”
Patrick Lucy, VP of Business Development - Pfenex.
Sign in to search the full transcript archive, filter by topic, and access every quote from Patrick Lucy.